-
Perospirone: Receptor Potency and Kv1.5
2026-09-19
Perospirone (SM-9018 free base) connects high-affinity serotonergic and dopaminergic receptor pharmacology with a newly characterized vascular Kv1.5 effect. This evidence-calibrated guide shows how to design assays that distinguish therapeutic target activity from concentration-dependent off-target channel modulation.
-
SCH772984 HCl: ERK1/2 Inhibitor Workflows
2026-09-19
Build cleaner MAPK experiments with SCH772984 HCl, from acute ERK signaling assays to resistance studies in BRAF- and RAS-mutant models. The workflow also shows how ERK inhibition can be paired with spatial translation readouts inspired by recent cardiomyocyte research.
-
VER 155008: HSP70 Inhibitor Evidence Guide
2026-09-18
VER 155008 is an adenosine-derived HSP 70 inhibitor that targets the ATPase pocket of Hsp70-family chaperones. Reported biochemical and cellular data support its use in Hsp70 ATPase activity studies, apoptosis assays, and cancer research, while mouse tumor data indicate a pharmacokinetic limitation.
-
Trametinib (GSK1120212) Experimental Workflows
2026-09-17
Build reproducible MEK-ERK pathway experiments with Trametinib (GSK1120212), from DMSO stock preparation to phospho-ERK, cell-cycle, apoptosis, and resistance readouts. The workflow also translates recent multi-omics findings into practical assays for comparing B-RAF-mutated and adaptive-resistant cancer models.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-17
This 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic transgene activity at the translation stage rather than by changing transcription. In mouse models, LIRP-enabled AAV systems used ambient or blue light to regulate metabolic and retinal therapies, illustrating a potentially reversible safety layer for gene and cell-based treatment.
-
Nintedanib (BIBF 1120): Mechanism & Workflow
2026-09-17
Nintedanib, also called BIBF 1120, is an orally active triple angiokinase inhibitor that targets VEGFR, FGFR, and PDGFR signaling. Its research value spans antiangiogenic cancer models, idiopathic pulmonary fibrosis treatment research, and ATRX-stratified receptor tyrosine kinase studies.
-
SCH772984: ERK Control for Radiosensitization
2026-09-16
A translational framework for using SCH772984 to connect ERK1/2 kinase control with radioresistance, ferroptosis biology, mutant-driven tumor models, and pharmacodynamic assay design.
-
Perospirone: Receptor and Kv1.5 Research Workflows
2026-09-15
Perospirone (SM-9018 free base) supports receptor-focused schizophrenia research while enabling a complementary investigation of vascular Kv1.5 channel inhibition. This guide translates its chemistry and pharmacology into practical assay workflows, controls, and troubleshooting strategies for neuropsychiatric and cardiovascular research.
-
Separating Growth Inhibition from Cell Death
2026-09-15
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from cell killing, improving the interpretation of potency, timing, and mechanism in cancer biology research.
-
ML133 HCl Workflow for Kir2.1 Research
2026-09-14
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with potassium ion transport, PASMC behavior, and vascular-remodeling signals. This practical guide translates published findings into concentration planning, assay workflows, controls, and troubleshooting decisions.
-
APEX2 Promotes Efficient TERT Expression in hESCs
2026-09-14
A bioRxiv study identifies APEX2, but not its paralog APEX1, as a determinant of efficient TERT expression and telomerase activity in human embryonic stem cells and melanoma cells. RNA sequencing and chromatin immunoprecipitation connect this effect to APEX2 occupancy near repeat elements, especially MIR sequences within TERT intron 2, suggesting a DNA repair–transcription interface.
-
MK-1775: Wee1 Kinase Inhibitor Workflow Guide
2026-09-13
Use MK-1775 to interrogate Wee1-dependent cell-cycle control, distinguish growth arrest from cell death, and test chemotherapy sensitization in p53-deficient cancer models. This workflow emphasizes time-resolved controls, quantitative viability metrics, and troubleshooting for reproducible checkpoint-abrogation studies.
-
Dexamethasone (DHAP) Research Workflows
2026-09-12
Dexamethasone (DHAP) supports controlled studies of NF-κB modulation, stem cell differentiation, autophagy, osteosarcoma growth, and neuroinflammation. This practical guide connects formulation, time-course design, route comparisons, and troubleshooting to improve assay reproducibility.
-
Better In Vitro Drug Response Metrics in Cancer
2026-09-12
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify whether an anticancer treatment mainly suppresses proliferation, induces cell death, or does both. The framework emphasizes measuring response magnitude and timing separately, improving interpretation of in vitro drug studies and their translation to mechanistic models.
-
Dihydroethidium (DHE): Reliable Superoxide Assays
2026-09-11
This scenario-driven guide explains how Dihydroethidium (DHE), SKU C3807, can support reproducible live-cell superoxide measurements alongside viability, proliferation, and cytotoxicity assays. It covers spectral selection, controls, solvent and storage constraints, interpretation limits, and practical vendor-selection criteria.